West Pharmaceutical (NYSE: WST) grants RSUs and options to SVP & General Counsel

Rhea-AI Filing Summary

West Pharmaceutical Services executive Norman D. Finch, Jr., who serves as SVP, General Counsel & Corporate Secretary, reported equity awards in the company’s stock. On December 8, 2025, he received 192 restricted stock units, each representing a right to receive one share of common stock. This award is scheduled to vest in four equal installments beginning December 8, 2026, providing a staggered long-term incentive.

On the same date, Finch also received a stock option covering 459 shares of West Pharmaceutical common stock at an exercise price of $269.08 per share, with an expiration date of December 8, 2035. Both the RSUs and the option are reported as directly owned and reflect standard equity-based compensation for a senior officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finch Norman D. Jr.

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GC & Corporate Secretary

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	$0	12/08/2025		A		192		(1)	(1)	Common Stock	192	$0	192	D
Stock Option (Right to Buy)	$269.08	12/08/2025		A		459		12/08/2026(1)	12/08/2035	Common Stock	459	$269.08	459	D

Explanation of Responses:

1. This award vests in four equal installments beginning on December 8, 2026.

	/s/ Louis Lalli, as an agent for Norman D. Finch, Jr.	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did WST report for Norman D. Finch, Jr.?

West Pharmaceutical Services reported that Norman D. Finch, Jr., SVP, General Counsel & Corporate Secretary, received restricted stock units and a stock option on December 8, 2025 as part of his equity compensation.

How many restricted stock units did Norman Finch receive from WST?

Norman Finch received 192 restricted stock units, each linked to one share of West Pharmaceutical Services common stock.

When do Norman Finch’s WST restricted stock units start vesting and over what schedule?

The 192 restricted stock units awarded to Norman Finch vest in four equal installments, beginning on December 8, 2026, creating a multi-year vesting schedule.

What are the key terms of the stock option granted to Norman Finch by West Pharmaceutical Services (WST)?

Norman Finch received a stock option for 459 shares of West Pharmaceutical common stock with an exercise price of $269.08 per share and an expiration date of December 8, 2035.

Is the equity reported in this WST Form 4 held directly or indirectly?

The filing shows that the restricted stock units and the stock option reported for Norman Finch are held with direct ownership.

What is Norman Finch’s role at West Pharmaceutical Services (WST)?

Norman D. Finch, Jr. is identified as an officer of West Pharmaceutical Services, serving as SVP, General Counsel & Corporate Secretary.